XEOMIN (incobotulinumtoxin A)

Content Contributor

XEOMIN (incobotulinumtoxin A) is derived from the Clostridium Botulinum bacteria to cause muscle paralysis at the site on injection. Initially approved for US in the US in 2010 for conditions of muscle spasticity; it was approved in 2011 for treatment of moderate tp severe glabellar lines (frown lines) by injecting into the corrugator and procerus muscles.

More recently it has has been approved to treat medical conditions of muscle spasticity in adults and children. For treatment of wrinkles, a small syringe is used along with a very fine needle. XEOMIN is then injected into the muscle underlaying the frown line wrinkles. Some providers may inject other areas, though this would be considered off label usage.

There is minimal pain or bruising with the procedure and the effects are expected to last up to four months. Treatment may safely be repeated every three months to block the appearance of frown line wrinkles.

Search Healthcare Topics Below:

Log in with your credentials


Forgot your details?

Create Account